Paper41533467
Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.
Munoz Mendoza J and 11 others. Clin J Am Soc Nephrol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy. Papers, record 41533467. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41533467
- Disease
- type 2 diabetes mellitus613 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Nephrectomy | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Renal Insufficiency, Chronic | Major topic |
| Albuminuria | Major topic |
| Naphthyridines | Major topic |
| Mineralocorticoid Receptor Antagonists | Major topic |
| Diabetic Nephropathies | Major topic |
| Humans | |
| Female | |
| Male | |
| Disease Progression | |
| Middle Aged | |
| Aged | |
| Treatment Outcome | |
| Hyperkalemia |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Bayer AG | PubMed |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02540993 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02545049 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease | Derived from the trial | Yes | ClinicalTrials.gov |
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27018509 | Proteinuria is a Predictor of Renal Functional Decline in Patients with Kidney Cancer. | J Urol | 2016 | https://conductscience.org/library/papers/27018509 | PubMed |
| 2 | 38788900 | Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2024 | https://conductscience.org/library/papers/38788900 | PubMed |
| 3 | 24704019 | Prospective measurement of urinary microalbumin in living kidney donor nephrectomy: toward understanding the renal functional recovery period. | J Urol | 2014 | https://conductscience.org/library/papers/24704019 | PubMed |
| 4 | 28926607 | The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. | PLoS One | 2017 | https://conductscience.org/library/papers/28926607 | PubMed |
| 5 | 25824808 | Nephrectomy for benign disease in the UK: results from the British Association of Urological Surgeons nephrectomy database. | BJU Int | 2016 | https://conductscience.org/library/papers/25824808 | PubMed |
| 6 | 27798198 | Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans. | Nephrol Dial Transplant | 2018 | https://conductscience.org/library/papers/27798198 | PubMed |
| 7 | 34599260 | Critical timing of ACEi initiation prevents compensatory glomerular hypertrophy in the remaining single kidney. | Sci Rep | 2021 | https://conductscience.org/library/papers/34599260 | PubMed |
| 8 | 37394174 | A Predictive Model for Kidney Failure After Nephrectomy for Localized Kidney Cancer: The Kidney Cancer Risk Equation. | Am J Kidney Dis | 2023 | https://conductscience.org/library/papers/37394174 | PubMed |
| 9 | 31665733 | Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. | Am J Nephrol | 2019 | https://conductscience.org/library/papers/31665733 | PubMed |
| 10 | 24621652 | Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. | J Cardiovasc Pharmacol | 2014 | https://conductscience.org/library/papers/24621652 | PubMed |
| 11 | 31935154 | Proteinuria as an independent predictor of stroke: Systematic review and meta-analysis. | Int J Stroke | 2020 | https://conductscience.org/library/papers/31935154 | PubMed |
| 12 | 18337713 | Long-term outcomes in nondiabetic chronic kidney disease. | Kidney Int | 2008 | https://conductscience.org/library/papers/18337713 | PubMed |
| 13 | 38048573 | Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. | Ann Intern Med | 2023 | https://conductscience.org/library/papers/38048573 | PubMed |
| 14 | 29018140 | Incident CKD after Radical or Partial Nephrectomy. | J Am Soc Nephrol | 2018 | https://conductscience.org/library/papers/29018140 | PubMed |
| 15 | 30635226 | Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. | Lancet Diabetes Endocrinol | 2019 | https://conductscience.org/library/papers/30635226 | PubMed |
| 16 | 25784968 | Impact of microalbuminuria on incident coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis of prospective studies. | Int J Clin Exp Med | 2015 | https://conductscience.org/library/papers/25784968 | PubMed |
| 17 | 11373357 | Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. | J Am Soc Nephrol | 2001 | https://conductscience.org/library/papers/11373357 | PubMed |
| 18 | 35023547 | Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. | Eur Heart J | 2022 | https://conductscience.org/library/papers/35023547 | PubMed |
| 19 | 24747655 | Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. | J Urol | 2014 | https://conductscience.org/library/papers/24747655 | PubMed |
| 20 | 11696703 | Renal outcome 25 years after donor nephrectomy. | J Urol | 2001 | https://conductscience.org/library/papers/11696703 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| FINERENONE | CHEMBL2181927 | Derived from the trial | 2 | https://conductscience.org/library/drugs/CHEMBL2181927 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Cited by
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41533467
GET https://conductscience.org/api/papers/v1/41533467/references?page=2